Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Prepetition Obligations Prepetition Obligations Top Unsecured Claims Top Unsecured Claims Events Leading to Bankruptcy Events Leading to Bankruptcy Post-COVID Macroeconomic and Industry Headwinds Since 2022, the Company has faced significant challenges attributable to a combination of post-COVID-19 operational difficulties and adverse macroeconomic conditions that eroded margins and tightened liquidity, exacerbated by a substantial debt burden accumulated through years of acquisition and by rising interest costs
Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial
pH level: 6.40 ~ 8.40
10.1136/gut.22.2.103 Gut 24 De DuveC.PressmanB
